Clinical trial
Study of gp75 Vaccine in Patients With Stage III and IV Melanoma
NCT00034554 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00034554 |
|---|---|
| Title | Study of gp75 Vaccine in Patients With Stage III and IV Melanoma |
| Official title | Phase I Study of gp75 DNA Vaccine in Patients With AJCC Stage III and IV Melanoma |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | Memorial Sloan Kettering Cancer Center |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Malignant Melanoma |
| Intervention type | Biological |
| Interventions | gp75 DNA vaccine |
| Enrollment | 31 |
| Start date | Mar 1, 2002 |
| Primary completion | Sep 1, 2004 |
| Completion | Sep 1, 2004 |
| First posted | May 1, 2002 |
| Last update posted | Apr 9, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: